Transplant outcomes of the entire cohort
| . | Overall . |
|---|---|
| Outcome∗ | % (95% CI) |
| aGVHD | |
| Grade 2-4 | 24 (22-27) |
| Grade 3-4 | 7 (6-9) |
| cGVHD | |
| Overall | 31 (28-35) |
| Extensive | 12 (10-15) |
| NRM | 12 (10-14) |
| Relapse incidence | 25 (22-27) |
| LFS | 64 (60-67) |
| OS | 70 (67-73) |
| GRFS | 52 (49-56) |
| . | Overall . |
|---|---|
| Outcome∗ | % (95% CI) |
| aGVHD | |
| Grade 2-4 | 24 (22-27) |
| Grade 3-4 | 7 (6-9) |
| cGVHD | |
| Overall | 31 (28-35) |
| Extensive | 12 (10-15) |
| NRM | 12 (10-14) |
| Relapse incidence | 25 (22-27) |
| LFS | 64 (60-67) |
| OS | 70 (67-73) |
| GRFS | 52 (49-56) |
aGVHD, acute GVHD; cGVHD, chronic GVHD.
Acute GVHD: 180-day cumulative incidence; cGVHD, NRM, and RI: cumulative incidence at 2 years; LFS, OS and GRFS: survival probability at 2 years.